The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) is a huge mover today! The stock increased 4.00% or $0.1 on November 23, hitting $2.6. About 68,020 shares traded hands. Harvard Bioscience, Inc. (NASDAQ:HBIO) has declined 16.67% since April 22, 2016 and is downtrending. It has underperformed by 22.08% the S&P500.
The move comes after 6 months positive chart setup for the $87.62 million company. It was reported on Nov, 24 by Barchart.com. We have $2.70 PT which if reached, will make NASDAQ:HBIO worth $3.50M more.
Analysts await Harvard Bioscience, Inc. (NASDAQ:HBIO) to report earnings on May, 5. They expect $0.02 EPS, up 100.00% or $0.01 from last year’s $0.01 per share. HBIO’s profit will be $674,000 for 32.50 P/E if the $0.02 EPS becomes a reality. After $0.01 actual EPS reported by Harvard Bioscience, Inc. for the previous quarter, Wall Street now forecasts 100.00% EPS growth.
Harvard Bioscience, Inc. (NASDAQ:HBIO) Ratings Coverage
Out of 2 analysts covering Harvard Bioscience Inc (NASDAQ:HBIO), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Harvard Bioscience Inc has been the topic of 2 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was initiated by Singular Research with “Buy” on Thursday, November 17. The firm earned “Buy” rating on Tuesday, July 28 by Benchmark.
According to Zacks Investment Research, “HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories.”
Insitutional Activity: The institutional sentiment increased to 0.94 in Q2 2016. Its up 0.18, from 0.76 in 2016Q1. The ratio increased, as 13 funds sold all Harvard Bioscience, Inc. shares owned while 32 reduced positions. 17 funds bought stakes while 17 increased positions. They now own 22.70 million shares or 4.80% less from 23.85 million shares in 2016Q1.
Segall Bryant & Hamill Limited Liability Corp accumulated 337,281 shares or 0.03% of the stock. Bard Associates reported 365,325 shares or 0.55% of all its holdings. Cornerstone Cap Mngmt Holding Ltd Com holds 0% or 67,751 shares in its portfolio. Teton, a New York-based fund reported 156,392 shares. Moreover, Bridgeway Capital Mngmt Incorporated has 0.01% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 251,117 shares. New York State Common Retirement Fund has 9,200 shares for 0% of their US portfolio. Dimensional Fund Advsr L P has 0% invested in the company for 1.61M shares. Renaissance Techs Limited Com holds 534,200 shares or 0% of its portfolio. Meristem Llp last reported 12,368 shares in the company. Blackrock Institutional Trust Na holds 0% or 1.11M shares in its portfolio. California Public Employees Retirement Sys has 139,202 shares for 0% of their US portfolio. Alpine Partners Vi holds 0.03% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 24,782 shares. Nationwide Fund Advsr has 8,872 shares for 0% of their US portfolio. Earnest Prtn Ltd Liability has invested 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Schwab Charles Investment holds 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 19,300 shares.
Insider Transactions: Since November 2, 2016, the stock had 2 insider purchases, and 0 selling transactions for $94,750 net activity. The insider Duchemin Jeffrey bought 15,000 shares worth $36,300. Shares for $58,450 were bought by Gagnon Robert E. on Wednesday, November 2.
Another recent and important Harvard Bioscience, Inc. (NASDAQ:HBIO) news was published by Quotes.Wsj.com which published an article titled: “News Harvard Bioscience Inc.HBIO” on February 11, 2011.
HBIO Company Profile
Harvard Bioscience, Inc., incorporated on October 8, 2000, is a developer, maker and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Firm sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.